Senseonics Holdings, Inc. (NYSE:SENS) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Senseonics Holdings, Inc. has received a consensus "Buy" recommendation from five analysts, with an average target price of $1.5375.
• The company's stock is set to undergo a 1-for-20 reverse split on October 20th, impacting the number of shares held by shareholders.
• Senseonics specializes in continuous glucose monitoring (CGM) systems for diabetes management, including products like Eversense and Eversense XL.

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) has earned a consensus recommendation of "Buy" from the five ratings firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $1.5375.

Several equities analysts recently issued reports on the company. Barclays assumed coverage on Senseonics in a report on Wednesday, August 27th. They set an "overweight" rating and a $1.50 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $1.40 price objective (up from $1.10) on shares of Senseonics in a report on Tuesday, July 8th. TD Cowen initiated coverage on Senseonics in a report on Tuesday, July 15th. They issued a "buy" rating and a $1.25 price target for the company. Finally, Lake Street Capital raised Senseonics to a "strong-buy" rating in a report on Thursday, July 17th.

Senseonics Stock Performance

Shares of SENS stock opened at $0.44 on Thursday. The stock has a fifty day moving average price of $0.46 and a 200 day moving average price of $0.53. The stock has a market cap of $360.90 million, a PE ratio of -3.41 and a beta of 0.83. Senseonics has a 1 year low of $0.25 and a 1 year high of $1.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47.

Senseonics's stock is going to reverse split on Monday, October 20th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 19th.

Hedge Funds Weigh In On Senseonics

A number of institutional investors have recently made changes to their positions in SENS. CTC Alternative Strategies Ltd. acquired a new position in shares of Senseonics in the first quarter worth $31,000. IFP Advisors Inc raised its holdings in shares of Senseonics by 120.9% in the first quarter. IFP Advisors Inc now owns 47,500 shares of the company's stock worth $31,000 after acquiring an additional 26,000 shares during the last quarter. Elite Life Management LLC acquired a new position in shares of Senseonics in the second quarter worth $36,000. Smith Salley Wealth Management acquired a new position in shares of Senseonics in the first quarter worth $36,000. Finally, HBK Sorce Advisory LLC purchased a new stake in shares of Senseonics in the third quarter valued at $39,000. 12.36% of the stock is owned by institutional investors and hedge funds.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.